Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Moderna, Inc.    MRNA


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Moderna, Inc. : The beginning of the move

11/20/2020 | 11:57am EST
11/20/2020 | 11:57am EST
long trade
Target price hit
Entry price : 97.4434$ | Target : 110$ | Stop-loss : 88$ | Potential : 12.89%
Moderna, Inc. shares have been in strong demand lately. The technical chart pattern looks positive which may give rise to new gains.
Investors have an opportunity to buy the stock and target the $ 110.
Moderna, Inc. : Moderna, Inc. : The beginning of the move
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • For the past twelve months, EPS forecast has been revised upwards.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 47.93 USD

  • Stock prices approach a strong long-term resistance in weekly data at USD 94.85.
  • Technically, the stock approaches a strong medium-term resistance at USD 97.95.
  • Low profitability weakens the company.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The company's "enterprise value to sales" ratio is among the highest in the world.

© Zonebourse.com 2020

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (USD)
Sales 2020 449 M - -
Net income 2020 -673 M - -
Net cash 2020 2 547 M - -
P/E ratio 2020 -88,1x
Yield 2020 -
Capitalization 50 267 M 50 267 M -
EV / Sales 2020 106x
EV / Sales 2021 7,46x
Nbr of Employees 1 100
Free-Float 90,0%
Upcoming event on MODERNA, INC.
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 108,41 $
Last Close Price 127,03 $
Spread / Highest target 30,7%
Spread / Average Target -14,7%
Spread / Lowest Target -52,8%
EPS Revisions
Stéphane Bancel Chief Executive Officer & Director
Stephen Hoge President
Noubar B. Afeyan Chairman
David W. Meline Chief Financial Officer
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capitalization (M$)
MODERNA, INC.549.44%50 267
LONZA GROUP AG55.15%44 901
CELLTRION, INC.82.04%39 811
SEAGEN INC.48.01%29 832
IMMUNOMEDICS, INC.315.22%20 324